Features of polymyalgia rheumatica–like syndrome after immune checkpoint inhibitor therapy
Features of polymyalgia rheumatica–like syndrome after immune checkpoint inhibitor therapy
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
Among the five other patients, one received methotrexate, three received tocilizumab (one who responded, one who had primary failure and one who had drug-induced hepatitis) and one healed after ICI disruption.Table 1 Characteristics of ICI+PMR compared with ICI−PMR ICI+PMR (n=14) ICI−PMR (n=43) Women (%) 2 (14.3) 26 (39.5) Patients over 50 years ol...
Alternative Titles
Full title
Features of polymyalgia rheumatica–like syndrome after immune checkpoint inhibitor therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2379032902
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2379032902
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2020-217225
